Clinical trials: Bee Venom Allergy
Hymenoptera Venom Allergy
Virtual-reality Induced Immune Modulation in Allergic Patients
This study investigates whether immersive virtual reality (VR) exposure to allergen-related stimuli can modulate behavioural, neurophysiological, psychophysiological, and immune responses in adults with bee or wasp venom allergy.
- Trial name
- NCT07721233
- Testing
- Allergen-related immersive virtual reality exposure, Control immersive virtual reality exposure
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Geneva, Switzerland
Bee Venom Allergy
Efficacy and Safety of a Purified Standardised Bee Venom Preparation
The trial is performed to assess efficacy and safety of a purified standardised bee venom preparation in bee venom allergy
- Trial name
- NCT00263952
- Testing
- bee venom
- Where
- Germany
- Sponsor
- Allergopharma GmbH & Co. KG
Bee Venom Allergy
Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure
Venom immunotherapy (VIT) is an established treatment for Hymenoptera venom allergy and provides long-term protection from further generalized reactions in almost all patients.
- Trial name
- PREDICT (NCT04259359)
- Testing
- Insect Venom
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 266 people
- Sponsor
- Medical University of Graz
Birch Pollen Allergy, Grass Pollen Allergy
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
About 20% of the general population are affected by an allergy - with an upward trend. Quite often, allergic people do not consider their disease as serious and suffer from subsequent complications, like allergic asthma, later in…
- Conditions
- Birch Pollen Allergy, Grass Pollen Allergy, House Dust Mite Allergy, Cat Allergy
- Trial name
- MADMAX (NCT04435678)
- Testing
- ALEX² test using the MAX 45k automated laboratory system
- Where
- 2 sites in Austria
- Volunteers
- 839 people
- Sponsor
- MacroArray Diagnostics GmbH
Venom Allergy
Maintenance Bee-Venom Immunotherapy Administered at 6-Month Intervals Does Not Protect Against re-Stings
Maintenance venom immunotherapy administered at 6-month intervals to bee-venom allergic patients failed to provide protection from systemic reactions after sting challenges.
- Trial name
- NCT00684476
- Testing
- venom immunotherapy
- Volunteers
- 60 people
- Sponsor
- Meir Medical Center
Allergy, Bee Venom
Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions
The purpose of this study is to evaluate if omalizumab co-treatment may allow reintroduction of honey bee venom immunotherapy in patients with immunotherapy treatment failure due to systemic reactions.
- Conditions
- Allergy, Bee Venom, Immunotherapy, Omalizumab
- Trial name
- NCT02968394
- Testing
- omalizumab
- Where
- Slovenia
- Volunteers
- 11 people
- Sponsor
- The University Clinic of Pulmonary and Allergic Diseases Golnik